The latest announcement is out from Pyxis Oncology ( (PYXS) ).
On March 18, 2025, Pyxis Oncology announced the resignation of Ken Kobayashi, M.D., as Chief Medical Officer, with Lara S. Sullivan, M.D., assuming the role alongside her current duties as President and CEO. The company also reported positive preliminary data from its Phase 1 trial of micvotabart pelidotin, receiving Fast Track Designation from the FDA for treating certain head and neck cancers, and initiated further clinical trials, including a combination study with Merck’s KEYTRUDA®. Pyxis Oncology has streamlined its operations, reducing its workforce by 20% to focus on advancing the MICVO clinical program, and expects its cash runway to extend into the second half of 2026.
More about Pyxis Oncology
Pyxis Oncology, Inc. is a clinical-stage company focused on developing next-generation therapeutics for difficult-to-treat cancers. The company’s lead product candidate, micvotabart pelidotin (MICVO), is an antibody-drug conjugate targeting Extradomain-B Fibronectin, designed to treat recurrent and metastatic head and neck squamous cell carcinoma.
YTD Price Performance: -31.36%
Average Trading Volume: 669,234
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $66.01M
For a thorough assessment of PYXS stock, go to TipRanks’ Stock Analysis page.